11.5 Hormone therapy is the preferred front-line systemic therapy for patients with V A 100% yes (34 voters) hormone receptor positive tumours grade 1 or 2 and without rapidly – progressive disease 11.6 Progestogens (e.g. MPA 200 mg or MA 160 mg) are generally recommended III A 100% yes (34 voters) 11.7 hormonal agents to consider after progestins include tamoxifen, III C 100% yes (34 voters) fulvestrant and aromatase inhibitors 11.8 The standard of care is six cycles of 3-weekly carboplatin and paclitaxel. This I A 100% yes (34 voters) is on the preliminary communication of a randomised showing similar efficacy and less toxicity compared with cisplatin/doxorubicin/paclitaxel 11.9 There is no standard of care for second-line chemotherapy V C 100% yes (34 voters) 12. What are the most promising targeted agents and which study designs should be used to evaluate their clinical benefit? Recommendations: 12.1 PI3K/PTEN/AKT/mTOR pathway, PTEN, RAS-MAPK, angiogenesis III B 100% yes (34 voters) (especially and VEGF/VEGFR), ER/PgR and HRD/MSI are altered in endometrial cancer and their relevance should be studied in clinical trials with targeted agents
11.5 Hormone therapy is the preferred front-line systemic therapy for patients with hormone receptor positive tumours – grade 1 or 2 and without rapidly progressive disease V A 100% yes (34 voters) 11.6 Progestogens (e.g. MPA 200 mg or MA 160 mg) are generally recommended III A 100% yes (34 voters) 11.7 hormonal agents to consider after progestins include tamoxifen, fulvestrant and aromatase inhibitors III C 100% yes (34 voters) 11.8 The standard of care is six cycles of 3-weekly carboplatin and paclitaxel. This is on the preliminary communication of a randomised showing similar efficacy and less toxicity compared with cisplatin/doxorubicin/paclitaxel I A 100% yes (34 voters) 11.9 There is no standard of care for second-line chemotherapy V C 100% yes (34 voters) 12. What are the most promising targeted agents and which study designs should be used to evaluate their clinical benefit? Recommendations: 12.1 PI3K/PTEN/AKT/mTOR pathway, PTEN, RAS-MAPK, angiogenesis (especially and VEGF/VEGFR), ER/PgR and HRD/MSI are altered in endometrial cancer and their relevance should be studied in clinical trials with targeted agents III B 100% yes (34 voters)
IGC_2015_12_02_ESMO_1_SDC1.docx